Open innovation: A real option to restore value to the biopharmaceutical R&D

International Journal of Production Economics

Volumn 149, Issue , 2014, Pages 183-193

  Lo Nigro, Giovanna ^a   Morreale, Azzurra ^a   Enea, Gianluca ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Ernst and Young Financial and Business Advisors Spa   (Italy)

Author keywords

Biopharmaceutical industry; Licensing; Open innovation; R D portfolio; Real options analysis

Indexed keywords

BIOPHARMACEUTICAL INDUSTRY; CLOSED-FORM MODELING; DEVELOPMENT STAGES; NEW BUSINESS MODELS; OPEN INNOVATION; PORTFOLIO SELECTION; PROJECT EVALUATION; REAL OPTIONS ANALYSIS;

INDUSTRY; INNOVATION; NUCLEAR REACTOR LICENSING; OPTIMIZATION; VALUE ENGINEERING;

PROJECT MANAGEMENT;

EID: 84893767751     PISSN: 09255273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpe.2013.02.004     Document Type: Conference Paper

References (48)

1. F. Black, and M. Scholes The pricing of options and corporate liabilities Journal of Political Economy 81 1973 637 654
2. Berzinsh, G.; Nechval, N.; Purgailis M.; 2006. Optimal investment decisions for a set of projects under conditions of uncertainty. In: Proceedings of IEEE International Conference Industrial Technology. (ICIT 2006), pp. 911-916.
3. M. Bianchi, A. Cavaliere, D. Chiaroni, F. Frattini, and V. Chiesa Organisational modes for open innovation in the bio-pharmaceutical industry: an exploratory analysis Technovation 31 1 2011 22 33
4. A. Bingham, and D. Spradlin The Open Innovation Marketplace: Creating Value in the Challenge Driven Enterprise 2011 FT Press New Jersey (US)
5. E.H. Bowman, and G.T. Moskowitz Real options analysis and strategic decision making Organization Science, Informs 12 6 2001 772 777
6. M. Brach, and D. Paxson A gene to drug venture: Poisson options analysis R&D Management 31 2001 203 214
7. C. Carlsson, and R. Fullér A fuzzy approach to real option valuation Fuzzy Sets and Systems 139 2003 297 312
8. D. Cassimon, P.J. Engelen, L. Thomassen, and M. Van Wouwe The valuation of a NDA using a 6-fold compound option Research Policy 33 2004 41 51
9. D. Cassimon, M. De Backer, P.J. Engelen, M. Van Wouwe, and V. Yordanov Incorporating technical risk in compound real option models to value a pharmaceutical R&D licensing opportunity Research Policy 40 2011 1200 1216
10. D. Cassimon, P.J. Engelen, and V. Yordanov Compound real option valuation with phase-specific volatility: a multi-phase mobile payments case study Technovation 31 2011 240 255
11. Chance, D.; 1998. Essays in Derivatives. New Hope, PA: Frank J. Fabozzi Associates, 323.
12. H. Chesbrough, and A.K. Crowther Beyond high-tech: early adopters of open innovation in other industries R&D Management 36 3 2006 229 236
13. N.A. Chriss Black-Scholes and Beyond 496 1997 McGraw-Hill New York
14. R.G. Cooper, S.J. Edgett, and E.J. Kleinshmidt Portfolio Management for New Products 1997 McMaster University Hamilton, ON
15. T. Copeland, and V. Antikarov Real Options - A Practioner's Guide 2001 Texere New York
16. J. Cox, S. Ross, and M. Rubenstein Option pricing: a simplified approach Journal of Financial Economics 7 1979 229 264
17. L. Dahlandera, and D.M. Gannb How open is innovation? Research Policy 39 2010 699 709
18. Dhankhar, A.; Evers, M.; Møller, M.; 2012. Escaping the sword of Damocles: toward a new future for pharmaceutical R&D, McKinsey Perspectives on Drug and Device R&D.
19. J. DiMasi, R.W. Hansen, and H.G. Grabowski The price of innovation: new estimates of drug development costs Journal of Health Economics 22 2003 151 185
20. Dixit, A.; Pindyck, R.; 1994. Investment under Uncertainty. Princeton University Press.
21. H. Eilat, B. Golany, and A. Shtub Constructing and evaluating balanced portfolios of R&Di projects with interactions: a DEA based methodology European Journal of Operational Research 172 2006 1018 1039
22. Enea, G.; Lo Nigro, G.; 2011a. An affordable way to implement real options to select optimal R&D portfolio, 22nd Annual POMS Conference, Operations Management The Enabling Link, 29 April to May 2, Reno, NV.
23. Enea, G.; Lo Nigro, G.; 2011b. A real options based model to select a balanced R&D portfolio, 15th Annual International Conference on Real Options, June 15-18, Turku.
24. T.B. Folta Governance and uncertainty: the tradeoff between administrative control and commitment Strategic Management Journal 19 11 1998 1007 1028
25. R. Geske The valuation of compound options Journal of Financial Economics 7 1979 63 81
26. A. Gupta, K.S. Pawara, and P. Smartb New product development in the pharmaceutical and telecommunication industries: a comparative study International Journal of Production Economics 106 2007 41 60
27. M. Hartmann, and A. Hassan Application of real options analysis for pharmaceutical R&D project valuation - empirical results from a survey Research Policy 35 2006 343 354
28. F. Hassanzadeh, M. Collan, and M. Modarres A technical note on "A fuzzy set approach for R&D portfolio selection using a real options valuation model" by Wang and Hwang (2007) Omega 39 2011 464 465
29. M.I. Kamien, and N.L. Schwartz Self-financing of an R&D project The American Economic Review 68 3 1978 252 261
30. S. Kellog, and J.M. Charnes Real options valuation for a biotechnology company Financial Analyst Journal 56 2000 76 84
31. V. Lazzarotti, F. Manzini, and L. Mari A model for R&D performance measurement International Journal of Production Economics 134 2011 212 223
32. U. Licthnthaler Open innovation: past research, current debates and future directions Academy of Management Perspective 25 1 2011 75 93
33. C.H. Loch, and K. Bode-Greuel Evaluating growth options as sources of value for pharmaceutical research projects R&D Management 31 2 2001 231 248
34. Lo Nigro, G.; Enea, G.; Morreale A.; 2012a. Real Option Analysis (ROA) Opens Innovation: the biopharmaceutical case, in Grubbström, R.W.; Hinteruhuber, H. (Eds.), Proceedings of the 17th International Working Seminar on Production Economics, February 20-24, Innsbruck.
35. G. Lo Nigro, G. Perrone, and S. Chiapparrone Governance forms drivers in bio-pharmaceutical inter-firm relationships International Journal of Production Economics 140 2012 604 613
36. R.C. Merton Option pricing when underlying stock returns are discontinuous Journal of Financial Economics 3 1976 124 144
37. S. Nicholson, P.M. Danzon, and J. Mccolough Biotech-pharmaceutical alliances as a signal of asset and firm quality Journal of Business 78 4 2005 1433 1464
38. E. Pennings, and O. Lint The option value of advanced R&D European Journal of Operational Research 103 1997 83 94
39. E. Pennings, and L. Sereno Evaluating pharmaceutical R&D under technical and economic uncertainty European Journal of Operational Research 212 2 2011 374 385
40. M. Perlitz, T. Peske, and R. Schrank Real options valuation: the new frontier in R&D project evaluation? R&D Management 29 3 1999 255 270
41. M.J. Rogers, and C.D. Maranas Valuation and design of pharmaceutical R&D licensing deals American Institute of Chemical Engineers Journal 51 1 2005 198 209
42. M. Rogers, J. Gupta, and C.D. Maranas Real options based analysis of optimal pharmaceutical research and development portfolios Industrial and Engineering Chemistry Research 41 2002 6607 6620
43. Sereno, L.; 2010. Real Options Valuation of Pharmaceutical Patents: a Case Study (February 3, 2010). Available at: 〈http://ssrn. com/abstract=1547185âŒ.
44. R. Shockley, S. Curtis, J. Jafari, and K. Tibbs The option value of an early-stage biotechnology investment Journal of Applied Corporate Finance 15 2003 44 55
45. Trigeorgis, L.; 1996. Real Options: Managerial Flexibility and Strategy in Resource Allocation, MIT Press, Cambridge, MA.
46. W. Vanhaverbeke, V. Van de Vrande, and H. Chesbrough Understanding the advantages of open innovation practices in corporate venturing in terms of real options Creativity and Innovation Managment 17 2008 251 258
47. R.S. Vassolo, J. Anand, and T.B. Folta Non-additivity in portfolios of exploration activities: a real options-based analysis of equity alliances in biotechnology Strategic Management Journal 25 2004 1045 1061
48. J. Wang, and W.L. Hwang A fuzzy set approach for R&D portfolio selection using a real options valuation model Omega 35 3 2007 247 257